{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:28:23Z","timestamp":1786987703094,"version":"build-2736575974"},"reference-count":21,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.dmd.2026.100305","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T23:14:23Z","timestamp":1776467663000},"page":"100305","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Rapid assessment of metabolism and disposition of conjugated oligonucleotide vutrisiran in rats using a sensitive LC-HRMS platform"],"prefix":"10.1016","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4905-3993","authenticated-orcid":false,"given":"Peng","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4223-8089","authenticated-orcid":false,"given":"Xianqing","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiamin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gengyao","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1000-3462","authenticated-orcid":false,"given":"Hong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9286-9022","authenticated-orcid":false,"given":"Weiqun","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1996-1847","authenticated-orcid":false,"given":"Mingshe","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4923-8097","authenticated-orcid":false,"given":"Yi","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.dmd.2026.100305_bib1","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.cmet.2018.03.004","article-title":"RNA-Targeted therapeutics","volume":"27","author":"Crooke","year":"2018","journal-title":"Cell Metab"},{"issue":"3","key":"10.1016\/j.dmd.2026.100305_bib2","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/nbt.3765","article-title":"The chemical evolution of oligonucleotide therapies of clinical utility","volume":"35","author":"Khvorova","year":"2017","journal-title":"Nat Biotechnol"},{"issue":"7","key":"10.1016\/j.dmd.2026.100305_bib3","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1124\/dmd.121.000381","article-title":"Nonclinical pharmacokinetics and absorption, distribution, metabolism, and excretion of givosiran, the first approved n-acetylgalactosamine-conjugated RNA interference therapeutic","volume":"49","author":"Li","year":"2021","journal-title":"Drug Metab Dispos"},{"issue":"16","key":"10.1016\/j.dmd.2026.100305_bib4","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.4155\/fmc.15.144","article-title":"Oligonucleotide therapeutics: chemistry, delivery and clinical progress","volume":"7","author":"Sharma","year":"2015","journal-title":"Future Med Chem"},{"issue":"21","key":"10.1016\/j.dmd.2026.100305_bib5","doi-asserted-by":"crossref","first-page":"9645","DOI":"10.1021\/acs.jmedchem.6b00551","article-title":"The medicinal chemistry of therapeutic oligonucleotides","volume":"59","author":"Brad Wan","year":"2016","journal-title":"J Med Chem"},{"issue":"6","key":"10.1016\/j.dmd.2026.100305_bib6","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1093\/nar\/gkad067","article-title":"Chemistry, structure and function of approved oligonucleotide therapeutics","volume":"51","author":"Egli","year":"2023","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"10.1016\/j.dmd.2026.100305_bib7","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41392-020-0207-x","article-title":"Therapeutic SiRNA: state of the art","volume":"5","author":"Hu","year":"2020","journal-title":"Signal Transduct Target Ther"},{"issue":"10","key":"10.1016\/j.dmd.2026.100305_bib8","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1016\/j.drudis.2018.05.030","article-title":"Drug metabolism and pharmacokinetic strategies for oligonucleotide- and MRNA-based drug development","volume":"23","author":"Andersson","year":"2018","journal-title":"Drug Discov Today"},{"issue":"4","key":"10.1016\/j.dmd.2026.100305_bib9","doi-asserted-by":"crossref","first-page":"447","DOI":"10.4155\/bio.13.319","article-title":"Quantification of oligonucleotides by LC-MS\/MS: the challenges of quantifying a phosphorothioate oligonucleotide and multiple metabolites","volume":"6","author":"Ewles","year":"2014","journal-title":"Bioanalysis"},{"issue":"2","key":"10.1016\/j.dmd.2026.100305_bib10","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.jpba.2007.01.042","article-title":"Application of LC-MS for quantitative analysis and metabolite identification of therapeutic oligonucleotides","volume":"44","author":"Lin","year":"2007","journal-title":"J Pharm Biomed Anal"},{"key":"10.1016\/j.dmd.2026.100305_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchromb.2025.124505","article-title":"Automatic identification of oligonucleotide metabolites in complex biological samples using ultra high-performance liquid chromatography high-resolution mass spectrometry combined with the molecule profiler software","volume":"1254","author":"Ye","year":"2025","journal-title":"J Chromatogr B Anal Technol Biomed Life Sci"},{"issue":"24","key":"10.1016\/j.dmd.2026.100305_bib12","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232415474","article-title":"Bioanalysis of oligonucleotide by LC\u2013MS: effects of ion pairing regents and recent advances in ion-pairing-free analytical strategies","volume":"23","author":"Liu","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.dmd.2026.100305_bib13","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1002\/mas.21641","article-title":"Bioanalysis and biotransformation of oligonucleotide therapeutics by liquid chromatography-mass spectrometry","volume":"40","author":"Sutton","year":"2021","journal-title":"Mass Spectrom Rev"},{"issue":"10","key":"10.1016\/j.dmd.2026.100305_bib14","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1124\/dmd.123.001370","article-title":"In vivo metabolite profiles of an N-acetylgalactosamine\u2013conjugated antisense oligonucleotide AZD8233 using liquid chromatography high-resolution mass spectrometry: a cross-species comparison in animals and humans","volume":"51","author":"Li","year":"2023","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmd.2026.100305_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.microc.2024.110797","article-title":"Metabolite profiling of chemically modified oligonucleotides in rat liver homogenates using hydrophilic interaction liquid chromatography-high resolution mass spectrometry","volume":"202","author":"Liu","year":"2024","journal-title":"Microchem J"},{"issue":"13","key":"10.1016\/j.dmd.2026.100305_bib17","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1007\/s40265-022-01765-5","article-title":"Vutrisiran: first approval","volume":"82","author":"Keam","year":"2022","journal-title":"Drugs"},{"issue":"5","key":"10.1016\/j.dmd.2026.100305_bib20","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1089\/nat.2023.0011","article-title":"OSWG recommended approaches to the nonclinical pharmacokinetic (ADME) characterization of therapeutic oligonucleotides","volume":"33","author":"Berman","year":"2023","journal-title":"Nucleic Acid Ther"},{"issue":"3","key":"10.1016\/j.dmd.2026.100305_bib21","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1038\/clpt.1981.56","article-title":"Determination of mean valproic acid serum level by assay of a single pooled sample","volume":"29","author":"Hamilton","year":"1981","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.dmd.2026.100305_bib22","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/cpt.1974","article-title":"Single-dose pharmacokinetics and pharmacodynamics of transthyretin targeting N-acetylgalactosamine\u2013small interfering ribonucleic acid conjugate, vutrisiran, in healthy subjects","volume":"109","author":"Habtemariam","year":"2021","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.dmd.2026.100305_bib23","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1089\/nat.2018.0736","article-title":"GalNAc-SiRNA conjugates: leading the way for delivery of RNAi therapeutics","volume":"28","author":"Springer","year":"2018","journal-title":"Nucleic Acid Ther"},{"issue":"12","key":"10.1016\/j.dmd.2026.100305_bib24","doi-asserted-by":"crossref","first-page":"6821","DOI":"10.1021\/acs.analchem.7b01244","article-title":"Identification of GalNAc-conjugated antisense oligonucleotide metabolites using an untargeted and generic approach based on high resolution mass spectrometry","volume":"89","author":"Husser","year":"2017","journal-title":"Anal Chem"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955626000747?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955626000747?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T10:24:25Z","timestamp":1782383065000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955626000747"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S0090955626000747"],"URL":"https:\/\/doi.org\/10.1016\/j.dmd.2026.100305","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rapid assessment of metabolism and disposition of conjugated oligonucleotide vutrisiran in rats using a sensitive LC-HRMS platform","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dmd.2026.100305","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of American Society for Pharmacology and Experimental Therapeutics.","name":"copyright","label":"Copyright"}],"article-number":"100305"}}